A true endocrine disorder can slow weight reduction, alter appetite, increase fluid retention, and worsen body composition, but the phrase hormonal imbalance is too vague to explain a plateau by itself.
Oily skin is a common skin type characterized by excess sebum production. While sebum is necessary for keeping the skin moisturized and protected, an overproduction can lead to a shiny appearance, clogged pores, and acne. Understanding the causes, managing symptoms, and finding effective solutions are crucial for maintaining healthy skin. In this article, we will […]
You cannot erase inherited sequence through willpower, but you can change the pathway from genetic susceptibility to obesity through environmental design, appetite treatment, exercise, medication, and surgery.
Common variants near FTO can increase obesity susceptibility, often through appetite and satiety pathways, but they are not a genetic sentence and do not explain an individual’s entire weight history.
Insulin resistance can increase hunger, liver fat, glucose variability, and cardiometabolic risk while fasting glucose remains normal. It can make weight control harder, but it does not make a calorie deficit physiologically impossible.
Normal fasting glucose or HbA1c can coexist with hyperinsulinemia, visceral adiposity, fatty liver, hypertension, dyslipidemia, sleep apnea, and rising cardiovascular risk.
Every patient deserves endocrine clinical assessment, but not every patient needs an indiscriminate hormone panel before obesity treatment begins.
Parents transmit genes, appetite traits, household environments, early-life exposures, cultural routines, and socioeconomic constraints. Childhood obesity is inherited through a system, not one route.
After semaglutide is stopped, appetite suppression fades, biological pressure to regain can return, and many patients recover a substantial portion of lost weight. The outcome is variable, not inevitable in the same degree.
Tirzepatide generally produces greater average weight loss than semaglutide in obesity trials, but the correct comparison uses obesity brands and doses, not casual brand substitution.